Peel Hunt Reaffirms Hold Rating for Circassia Pharmaceuticals (CIR)

Circassia Pharmaceuticals (LON:CIR)‘s stock had its “hold” rating reiterated by investment analysts at Peel Hunt in a report issued on Monday.

A number of other research firms have also weighed in on CIR. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Circassia Pharmaceuticals in a research note on Tuesday, April 24th. Numis Securities decreased their target price on shares of Circassia Pharmaceuticals from GBX 180 ($2.33) to GBX 140 ($1.81) and set a “buy” rating on the stock in a research note on Tuesday, April 24th.

Circassia Pharmaceuticals opened at GBX 77.90 ($1.01) on Monday, according to MarketBeat.com.

About Circassia Pharmaceuticals

Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally.

Recommended Story: Google Finance Portfolio Tips and Tricks

Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply